Abstract
Objective: The aim of the study is to evaluate the effect of L-Carnitine on the dynamics of inflammation, insulin resistance (IR), functional status of kidneys in the complex therapy of patients with coronary heart disease (CHD) in combination with prostate adenocarcinoma and renal dysfunction. Material and Methods: Forty two men with prostate adenocarcinoma and coronary heart disease were enrolled. The patients were randomly and blindly divided into 2 groups: Group I patients were treated with L-Carnitine in addition to standard treatment; Group II patients received only conventional treatment. Standard laboratory blood tests, lipid profile, glucose, renal and liver function tests, serum C-reactive protein (CRP), insulin, testosterone levels, echocardiographic examination were performed for all patients at baseline and after 10 days of treatment. Results:Median level of HOMA index was 3.1 [1.9; 4.8] mg/ml. Insulin resistance was established in 54.8% patients of Group I and 40% patients of control group (p<0.05). In Group I, the mean insulin index and HOMA index decreased by 15.4% (p=0.001) and 19.2% (p=0.003), respectively. The supplementation of L-Carnitine in standard therapy contributed to a significant decrease in serum creatinine level and an increase in the level of glomerular filtration rate (GFR) in Group I patients (p<0.05). Conclusion: The supplementation of L-Carnitine in the complex therapy of patients with coronary artery disease in combination with prostate adenocarcinoma contributes to a significant decrease in insulin resistance, improves the functional state of kidneys.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have